No Data
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
Indaptus Therapeutics Provides 2025 Outlook, Launching Decoy20 Combination Cohort With BeiGene's Tislelizumab, Expanding Clinical Sites Beyond 8, Updating Higher Dose Cohort, First Patient Dosed In Combination, Focus On Cancer Challenges
WUXI BIO sells overseas Assets, but not because of the biosecurity legislation.
By adjusting the Assets, WUXI BIO has released more space and will further increase its overseas investments.
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
WUXI BIO has once again divested overseas Assets! Merck takes over WUXI BIO's Ireland vaccine factory for 0.5 billion USD | Quick read announcement.
① WUXI BIO announced today that it will sell the Ireland vaccine factory to Merck for 0.5 billion USD; ② this vaccine factory was originally built to undertake Merck's vaccine contract manufacturing business; ③ not long ago, WUXI APPTEC also divested its WuXi ATU business in the USA and United Kingdom.
BeiGene Gains FDA Nod for TEVIMBRA, Marking Key Progress in Oncology Treatments